Organ transplant immunosuppressant drugs are the category of drugs which are administered to minimize the chances of organ rejection after transplantation. When a person undergoes any transplantation, the body recognizes the transplant as a foreign tissue and attacks it, resulting in rejection. These drugs dilute the immune system, hence reducing the reaction towards the transplant. The factors driving this market include the advancements made in tissue engineering and organ transplantations. These transplantations help in survival of many patients as well as enhance the quality of life. The lack of availability of organs and high cost of transplantation are the limitations for the growth of this market. The increase in use of tissue engineering for generation of implants provides growth opportunity to this market.

GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS THERAPEUTICS MARKET ANALYSIS

On the basis of therapeutics, this market is classified into heart transplant, lung transplant, kidney transplant and liver transplant. Kidney transplant has a well established market although heart transplant is expected to have potential growth. 

ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS GEOGRAPHY MARKET ANALYSIS

On the basis of geography, this market is classified into North America, Europe, Asia-Pacific and rest of the world (RoW). Asia-Pacific region is expected to have greater share in this market in the coming years. This growth would be due to promotion of medical tourism in these countries.

COMPETITIVE LANDSCAPE

The major companies included in the report are AstellasPharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc, and Hoffman La Roche. Key companies in the report are seeking for approval strategy for the commercialization of their pipeline drugs. Therefore, the companies are adopting approval and clearance as key developmental strategies. 

HIGH LEVEL ANALYSIS

Organ transplant immunosuppressant drugs market has accelerated the growth of rapid organ transplant by reducing the harmful side effects such as autoimmune diseases. These novel drug therapies are strategically analyzed in the report in order to provide comparative benefits. The report is also focusing on the regulatory issues and commercial mandate that are hindering the growth. Porter’s five forces model is strategically analyzed in the report to project current and future market scenarios. The value chain analysis of the organ transplant immunosuppressant drugs market is dealt strategically. Top wining strategies adopted by the key players competing in this market are critically analyzed through primaries.

KEY BENEFITS

• Intelligence from key market segments through top investment pockets would help in providing strategic assistance to decision markers. 
• Analysis of key market players and strategies adopted by them are dealt to give an insight on top contenders in the market
• This report gives a detailed analysis of drivers and factors limiting market expansion of organ transplant immunosuppressant drugs 
• Projections are made for the period of 2014-2020 by considering current market scenario and future potential
• Porter’s five forces and SWOT analysis discussed would help in making strategic decisions

KEY MARKET SEGMENTS

The global Organ transplant immunosuppressant drugs market is segmented into therapeutics, commercialized products and geography.

MARKET BY THERAPEUTICS

• Heart Transplant
• Lung Transplant
• Kidney Transplant
• Liver Transplant

MARKET BY COMMERCIALIZED PRODUCTS

• Zenapax
• Prograf
• Cellcept
• Myfortic
• Neoral

MARKET BY GEOGRAPHY

• North America
• Europe
• Asia-Pacific
• RoW